TG Therapeutics, Inc. (TGTX)
40.93
+0.77
(+1.92%)
USD |
NASDAQ |
Jun 08, 16:00
40.93
0.00 (0.00%)
After-Hours: 17:37
TG Therapeutics EPS Diluted (Quarterly) : 0.1236 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Krystal Biotech, Inc. | 1.833 |
| MAIA Biotechnology, Inc. | -0.1409 |
| Vericel Corp. | -0.1241 |
| Catalyst Pharmaceuticals, Inc. | 0.5022 |
| United Therapeutics Corp. | 5.824 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 19.78M |
| Revenue (Quarterly) | 204.92M |
| Total Expenses (Quarterly) | 185.14M |
| Enterprise Value | 6.387B |
| Gross Profit Margin (Quarterly) | 83.65% |
| Profit Margin (Quarterly) | 9.65% |
| Earnings Yield | 7.01% |
| Operating Earnings Yield | 2.27% |
| Normalized Earnings Yield | 7.127 |